Two new anti-viral drugs for COVID

Two new viral drugs promise to reduce the health burden from COVID.

So far, Covid vaccines have played a pivotal role in reducing Cases, Hospitalisations and Deaths from Covid.

Two new drugs, one from Pfizer and another from Merck promise to provide a new way to fight the virus in vulnerable people.

The oral pills from Pfizer is called Paxlovid. Paxlovid is a combination of two drugs. One drug is a new antiviral drug developed by Pfizer and is called PF-07321332. Another drug is called ritonavir, and ritonavir is already being used to treat HIV/Aids.

The Merck drug is known by the brand name Lagevrio [chemical name is molnupiravir]. This drug is approved by U.K. regulators and is ready to be used in the NHS. The Pfizer drug is yet to be evaluated by authorities for approval.


Lagevrio 200 mg hard capsules. eMC SPC

Ritonavir Mylan 100 mg film coated tablets. eMC SPC

Wiki. Paxlovid.

Guardian. Pfizer Covid pill ‘can cut hospitalisations and deaths by nearly 90%’
Experimental antiviral pill taken at home is highly effective at preventing deaths, trial suggests

Ian Sample Science editor
Fri 5 Nov 2021 14.10 GMT

Guardian. UK first to approve oral antiviral molnupiravir to treat Covid
Pill can be taken twice daily at home and priority will be given to elderly patients and those with health vulnerabilities

Ian Sample Science editor
Thu 4 Nov 2021 12.38 GMT

Daily Mail. Daily Covid cases fall again… by a FIFTH: Infections drop 22% in a week to 34,029 while deaths and admissions creep up just 3% – as ONS finds third wave has ‘likely peaked’ and EU’s crisis starts to overtake UK. By Connor Boyd Deputy Health Editor For Mailonline
16:45, 05 Nov 2021 , updated 23:06, 05 Nov 2021

Disclaimer: Please note – This blog is NOT medical advice. This blog is NOT a expert medical opinion on various topics. This blog is purely for information only and do check the sources where cited. Please DO consult your own doctor to discuss concerns and options relevant to you. The views expressed in this blog are NOT, in way whatsoever, intended to be a substitute for professional advice. The blog is NOT previewed, commissioned or otherwise endorsed, in any way, by any organisation that the author is associated with. The views expressed in this blog likely represents some of the author’s personal views held at the time of drafting the blog and MAY CHANGE overtime, particularly when new evidence comes to light.